以岭药业获得“盐酸美金刚”化学原料药上市申请批准

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Wanyuan Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of Memantine Hydrochloride, a chemical raw material drug [1] Group 1: Company Information - Yiling Pharmaceutical's subsidiary, Hengshui Wanyuan, submitted the listing application for Memantine Hydrochloride, which has now been approved [1] - Memantine Hydrochloride is a voltage-dependent, moderate-affinity, non-competitive NMDA receptor antagonist that can block pathological increases in glutamate concentration, leading to neuronal damage [1] Group 2: Industry Context - Memantine Hydrochloride is used for the treatment of moderate to severe Alzheimer's disease [1]